ProNAi Therapeutics

Developing targeted therapies for patients with cancer

ProNAi Therapeutics (NASDAQ: DNAI) is focused on building a broad and diverse pipeline of oncology assets against emerging targets on the leading edge of cancer biology. The company’s portfolio includes PNT141, a small molecule inhibitor of Cdc7 kinase, which is a key regulator of both DNA replication and DNA damage response.

Status

IPO in 2015 (NASDAQ: DNAI)

Year of Investment

2014

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Vancouver, British Columbia